Biomarin Historical Cash Flow
| BMRN Stock | USD 71.44 1.39 1.91% |
Analysis of Biomarin Pharmaceutical cash flow over time is an excellent tool to project Biomarin Pharmaceutical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 499.2 M or Begin Period Cash Flow of 792.9 M as it is a great indicator of Biomarin Pharmaceutical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.
Biomarin |
About Biomarin Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Biomarin balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Biomarin's non-liquid assets can be easily converted into cash.
Biomarin Pharmaceutical Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Biomarin Pharmaceutical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biomarin Pharmaceutical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Biomarin Pharmaceutical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's End Period Cash Flow is very stable compared to the past year. As of the 30th of March 2025, Change To Liabilities is likely to grow to about 71.3 M, though Change To Inventory is likely to grow to (60.4 M).
Biomarin Pharmaceutical cash flow statement Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (61.2M) | (35.1M) | (68.3M) | (157.1M) | (63.5M) | (60.4M) | |
| Change In Cash | 211.7M | (61.9M) | 137.3M | 30.6M | 187.7M | 197.1M | |
| Free Cash Flow | (52.2M) | 185.3M | 44.4M | 51.6M | 475.4M | 499.2M | |
| Change In Working Capital | (224.4M) | 66.0M | (96.4M) | (336.5M) | (216.4M) | (205.6M) | |
| Begin Period Cash Flow | 437.4M | 649.2M | 587.3M | 724.5M | 755.1M | 792.9M | |
| Other Cashflows From Financing Activities | 27.3M | 3.0M | (16.0M) | (85.8M) | (31.5M) | (29.9M) | |
| Depreciation | 105.2M | 108.0M | 102.0M | 104.4M | 96.4M | 52.0M | |
| Other Non Cash Items | 44.7M | 12.9M | (115.5M) | 61.6M | 7.3M | 7.0M | |
| Capital Expenditures | 137.5M | 119.2M | 131.5M | 107.6M | 85.4M | 88.8M | |
| Total Cash From Operating Activities | 85.4M | 304.5M | 175.9M | 159.3M | 572.8M | 601.5M | |
| Net Income | 859.1M | (64.1M) | 141.6M | 167.6M | 426.9M | 448.2M | |
| Total Cash From Financing Activities | 181.1M | (48K) | (18.7M) | (18.7M) | (526.4M) | (500.1M) | |
| End Period Cash Flow | 649.2M | 587.3M | 724.5M | 755.1M | 942.8M | 990.0M | |
| Change To Liabilities | 80.2M | (93.9M) | 12.4M | 59.0M | 67.9M | 71.3M | |
| Total Cashflows From Investing Activities | (31.0M) | (53.6M) | (366.3M) | (20.0M) | (18.0M) | (18.9M) | |
| Sale Purchase Of Stock | (50M) | (45.8M) | (54.3M) | (76.3M) | (68.7M) | (65.3M) | |
| Other Cashflows From Investing Activities | 89.6M | 22.7M | 103.3M | (10.9M) | (853K) | (895.7K) | |
| Stock Based Compensation | 189.7M | 197.3M | 196.3M | 207.1M | 202.5M | 131.8M | |
| Change To Account Receivables | (59.0M) | 65.6M | (82.0M) | (190.4M) | (57.9M) | (60.8M) | |
| Investments | 26.2M | (366.3M) | (20.0M) | (101.0M) | 136.5M | 143.3M | |
| Change Receivables | (54.3M) | (37.9M) | (59.0M) | 65.6M | 75.4M | 79.2M | |
| Net Borrowings | (5.1M) | 210.8M | (3.0M) | (2.6M) | (2.3M) | (2.2M) | |
| Cash And Cash Equivalents Changes | (104.0M) | (56.5M) | 211.7M | (61.9M) | (55.7M) | (52.9M) | |
| Cash Flows Other Operating | (18.7M) | (36.6M) | (10.3M) | 23.2M | 20.9M | 21.9M | |
| Change To Netincome | 56.7M | (671.6M) | 185.2M | 28.8M | 25.9M | 27.2M | |
| Change To Operating Activities | (32.8M) | (17.2M) | 19.8M | (5.1M) | (4.6M) | (4.8M) | |
| Exchange Rate Changes | (598K) | 902K | (1.2M) | (57K) | (65.6K) | (68.8K) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.